Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 5;22(1):403.
doi: 10.1186/s12905-022-01934-4.

COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS)

Bing Zhang  1 , Xiao Yu  2 , Jinxing Liu  2 , Jinbao Liu  3 , Pengfei Liu  4
Affiliations

COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS)

Bing Zhang et al. BMC Womens Health. .

Abstract

Background: In reports of adverse reactions following vaccination with the coronavirus disease 2019(COVID-19) vaccines, there have been fewer reports of concern for menstrual disorders in female.

Objective: Our study employed Vaccine Adverse Event Reporting System (VAERS) to investigate and analyze the relationship between COVID-19 Vaccines and menstrual disorders in female.

Methods: We collected reports of menstrual disorders in VAERS from July 2, 1990 to November 12, 2021, and performed a stratified analysis. The potential relationship between COVID-19 vaccine and reports of menstrual disorders was evaluated using the Reporting Odds Ratio (ROR) method.

Results: A total of 14,431 reports of menstrual disorders were included in the study, and 13,118 were associated with COVID-19 vaccine. The ROR was 7.83 (95% confidence interval [95%CI]: 7.39-8.28). The most commonly reported event was Menstruation irregular (4998 reports), and a higher percentage of female aged 30-49 years reported menstrual disorders (42.55%) after exposure to COVID-19 Vaccines. Both for all reports of menstrual disorders (ROR = 5.82; 95%CI: 4.93-6.95) and excluding reports of unknown age (ROR = 13.02; 95%CI: 10.89-15.56),suggest that female age may be associated with menstrual disorders after vaccination with the COVID-19 Vaccines.

Conclusion: There is a potential safety signal when the COVID-19 vaccine is administered to young adult female (30-49 years old), resulting in menstrual disorders in. However, due to the well-known limitations of spontaneous reporting data, it is challenging to explicity classify menstrual disorders as an adverse event of the COVID-19 Vaccines, and reports of adverse reactions to COVID-19 Vaccines in this age group should continue to be tracked.

Keywords: 30–49 years; COVID-19 vaccine; Menstrual disorders events; Risk signals; VAERS.

PubMed Disclaimer

Conflict of interest statement

Author Bing Zhang, Author Xiao Yu, Author Jinxing Liu, Author Jinbao Liu and Author Pengfei Liu declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow diagram of case inclusion in this study
See this image and copyright information in PMC

References

    1. Kevadiya BD, Machhi J, Herskovitz J, et al. Diagnostics for SARS-CoV-2 infections. Nat Mater. 2021;20(5):593–605. doi: 10.1038/s41563-020-00906-z. - DOI - PMC - PubMed
    1. Singh JA, Upshur REG. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. The Lancet Infect Dis. 2021;21(4):e103–e109. doi: 10.1016/S1473-3099(20)30923-3. - DOI - PMC - PubMed
    1. Coccia M. Optimal levels of vaccination to reduce COVID-19 infected individuals and deaths: a global analysis. Environ Res. 2022;204(Pt C):112314. doi: 10.1016/j.envres.2021.112314. - DOI - PMC - PubMed
    1. Oliver SE, Gargano JW, Marin M, et al. The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Week Rep. 2020;69(50):1922–1924. doi: 10.15585/mmwr.mm6950e2. - DOI - PMC - PubMed
    1. Oliver SE, Gargano JW, Marin M, et al. The advisory committee on immunization practices' interim recommendation for use of Moderna COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Week Rep. 2021;69(5152):1653–1656. doi: 10.15585/mmwr.mm695152e1. - DOI - PMC - PubMed

Publication types